Adverse Drug Reaction [ADR]

Blog Archives

FDA safety communication concerning E-cigarettes

Posted on September 5, 2019 by by

thassodotcom Posted in Adverse Drug Reaction [ADR], New Safety Information, Regulatory Announcement, Thasso Post, Theragenomic Medicine No Comments ↓

September 05, 2019 – An E-cigarette is a handheld battery-powered vaporizer that simulates smoking by providing some of the behavioral aspects of smoking, including the hand-to-mouth action of smoking, but without burning tobacco. Using an E-cigarette is known as “vaping” and the user is referred to as a “vaper.”

…

Tags: Aerosol, Cannabinoid, Center for Disease Control and Prevention (CDC), E-Cigarette, E-Cigarette Legislation, E-Liquid, Tetrahydrocannabinol (THC), Thasso Post, Theragenomic Medicine, Tobacco Products Directive, Vaping, Vapor

Therapies that promote progressive multifocal leukoencephalopathy (PML)

Posted on August 23, 2019 by by

thassodotcom Posted in Adverse Drug Reaction [ADR], Commentary, Thasso Post, Theragenomic Medicine No Comments ↓

August 23, 2019 – Progressive multifocal leukoencephalopathy (PML) is a rare and often fatal viral disease characterized by progressive damage or inflammation of the white matter of the brain at multiple locations (i.e., multifocal). It is caused by the JC virus,

…

Tags: Abatacept (Orencia), Adalimumab (Humira), Alemtuzumab (Campath), Alemtuzumab (Lemtrada), Basiliximab (Simulaect), Belatacept [Nulojix], Belimumab (Benlista), Bevacizumab [Avastin], Brentuximab vedotin (Adectris), Carfizumab (Kyprolis), Cetuximab (Erbitux), Dimethyl Fumarate [Tecfidera], Efalizumab (Raptiva), Etanercept [Enbrel], Fingolimod (Gylenia), Ibritumomab tiuxetan (Zevalin), Immunosuppression, Infliximab [Remicade], JC Virus (JCV), Multiple Sclerosis (MS), Muromonab‐CD3 (Orthoclone OKT3), Natalizumab [Tysabri], Obinutuzumab (Gazyva), Ofatumumab (Arzerra), Progressive Multifocal Leukoencephalopathy (PML), Rituximab [Rituxan], Thasso Post, Theragenomic Medicine

Tofacitinib (Xeljanz): Dangers of blood clots in the lungs and of death

Posted on June 8, 2019 by by

thassodotcom Posted in Adverse Drug Reaction [ADR], New Safety Information, Thasso Post, Theragenomic Medicine No Comments ↓

June 08, 2019 – For some time now, Tofacitinib (Xeljanz) receives intense attention in the media, with regulatory authorities, and patients and treating physicians alike because of serious concerns of increased risk of blood clots in the lungs and increased mortality in patients treated for ulcerative colitis at the 10-mg twice-daily dose of Tofacitinib (Xeljanz).

…

Tags: Blood Clots in the Lungs, Bood Clotting, Death, Janus Kinase 1 (JAK1), Janus Kinase 3 (JAK 3), Psoriatic Arthritis, Pulmonary Embolism, Rheumatoid Arthritis, Thasso Post, Theragenomic Medicine, Tofacitinib (Xeljanz), Ulcerative Colitis

Lemtrada: Deleterious unwanted effects in some multiple sclerosis patients

Posted on April 19, 2019 by by

thassodotcom Posted in Adverse Drug Reaction [ADR], New Safety Information, Regulatory Announcement, Thasso Post, Theragenomic Medicine No Comments ↓

19 April 2019 – Alemtuzumab (Lemtrada) is used in the treatment of multiple sclerosis (MS). Moreover, Alemtuzumab, under the Tradenames of Campt, MabCampath and Campt-1H is on the markets for the treatment of chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma (CTCL),

…

Tags: Alemtuzumab, Alemtuzumab (Lemtrada), American Food & Drug Administration (FDA), Arterial Dissection, European Medicines Agency (EMA), Hemophagocytic Lymphohistiocytosis, Multiple Sclerosis (MS), Thasso Post, Theragenomics Medicine

Unlucky women with BIA-ALCL: An update

Posted on February 17, 2019 by by

thassodotcom Posted in Adverse Drug Reaction [ADR], New Safety Information, Thasso Post, Theragenomic Medicine No Comments ↓

February 17, 2019 – The unfortunate recognition of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a very rare form of a T-cell lymphoma, gains more momentum by the day. This is actually very positive a development, because it helps women who are getting breast implants for whatever reasons to better known associated health risks,

…

Tags: American Food & Drug Administration (FDA), Breast Implant, Health Canada, Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL), National Agency for the Safety of Medicines and Health Products (ANSM), Thasso Post, Theragenomics Medicine

Hydrochlorothiazide and non-melanoma skin cancer: How come?

Posted on February 2, 2019 by by

thassodotcom Posted in Adverse Drug Reaction [ADR], Regulatory Announcement, Thasso Post, Theragenomic Medicine No Comments ↓

February 02, 2019 – This is potential alarming news for millions of patients worldwide suffering from high blood pressure: Health Canada has just completed a safety review of hydrochlorothiazide and has found that prolonged use of the drug could increase a person’s risk for non-melanoma skin cancer.

…

Tags: Exforge HCT, Health Canada, High Blood Pressure, Hydrochlorothiazide, Non-Melanoma Skin Cancer, Thasso Post, Theragenomic Medicine

Febuxostat (Uloric) and its problem with cardiovascular mortality

Posted on January 16, 2019 by by

thassodotcom Posted in Adverse Drug Reaction [ADR], Regulatory Announcement, Thasso Post, Theragenomic Medicine 1 Comment ↓

January 16, 2109 – Despite drug safety problems of cardiovascular mortality with Febuxostat (Uloric), the benefits might still be seen to outweigh risks for selected gout patients. This notion may become more and disputed over time, however, for obvious reasons.

…

Tags: American Food & Drug Administration (FDA), Boxed Warning, Febuxostat (Uloric), Gout, Hyperuricemia, Increased Risk Of Death, Second Line Therapy, Thasso Post, Theragenomic Medicine

Cholangiocarcinoma: Diabetes Drugs In DPP-4 Inhibitor Class Associated With Doubled Risk

Posted on December 20, 2018 by by

thassodotcom Posted in Adverse Drug Reaction [ADR], Genetic Background, Genetic Predisposition, Genetic Susceptibility, Personalized Medicine, Thasso Post, Theragenomic Medicine No Comments ↓

…

Tags: Britisch Medical Journal (BMJ), Cholangiocarcinoma, Diabetes, Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, DPP-4 Inhibitor Class of Drugs, DPP4 Gene, GLP-1 Receptor Agonist, GLP1R Gene, Glucagon-Like Peptide-1 (GLP-1) Receptor, Glyxambi (Empagliflozin / Linagliptin), Janumet (Sitagliptin / Metformin), Januvia (Sitagliptin), Jentadueto (Linagliptin / Metformin), Kazano (Alogliptin / Metformin), Kombiglyze XR (Saxagliptin / Metformin), Nesina (Alogliptin), Onglyza (Saxagliptin), Oseni (Alogliptin / Pioglitazone), Qtern (Dapagliflozin / Saxagliptin), Thasso Post, Theragenomic Medicine, Tradjenta (Linagliptin)

CRISPR/Cas9 for the Treatment of Duchenne Muscular Dystrophy: Prime time already?

Posted on December 12, 2018 by by

thassodotcom Posted in Adverse Drug Reaction [ADR], Allelic Variant, Children, Clinical Development, Congenital, Gene Therapy, Genetic Predisposition, In The Press, Personalized Medicine, Rare Diseases, Thasso Post, Theragenomic Medicine No Comments ↓

December 12, 2018 – The application of CRISPR/Cas9 based molecular technology in the field of gene editing (or genome editing) has recently had its exploded limelight exposure for a couple of reasons. The question arises if this exposure is earned or somewhat premature.

…

Tags: CCR 5 Gene, CRISPR-Cas9, Duchenne Muscular Dystrophy, Dystrophin Gene (DMD), Embryonal Gene Editing, Exxon Skipping Therapy, Fatal X-linked recessive Neuromuscular Disease, Gene Editing, Genetically Edited Babies, Hypertrophic Cardiomyopathy (HCM), Immune Response Activation, MYBCP3 Gene, Off-Targeting, Sub-Optimal In Vivo Delivery, Thasso Post, Theragenomic Medicine, Translation Into The Clinic

Cancer therapies: Immune checkpoint inhibitors may kill you

Posted on October 21, 2018 by by

thassodotcom Posted in Adverse Drug Reaction [ADR], New Research, New Safety Information, Thasso Post, Theragenomic Medicine No Comments ↓

October 21, 2018 – In a study published online September 13 in JAMA Oncology, the authors just reminded us of the fact that besides all hype about immune checkpoint inhibitors (ICIs) in the cancer therapy field,

…